NewsAI-assisted

Breckenridge Pharmaceutical Recalls One Lot of Propranolol Capsules

Breckenridge Pharmaceutical recalls one lot of Propranolol 60 mg capsules after metal contamination traced to shared intermediate material from Adare Pharma Solutions.

Vaibhavi M.
By Vaibhavi M.
Subject Matter Expert · Pharma Now
Nov 21, 2026Updated Nov 22, 2026 · 2 min read
Breckenridge Pharmaceutical Recalls One Lot of Propranolol Capsules
AI-assisted reporting
Reviewed by Vaibhavi M., Subject Matter Expert · Pharma Now
100/ 100
Trust score
High confidence

A shared intermediate material supplied by contract manufacturer Adare Pharma Solutions is the suspected contamination pathway behind Breckenridge Pharmaceutical's voluntary consumer-level recall of one lot of Propranolol Hydrochloride Extended-Release Capsules, USP, 60 mg, a sequence that puts intermediate material segregation controls and supplier quality oversight squarely in focus for QA directors and plant heads.

The recall, announced November 16, 2026 and published by FDA on November 20, covers lot PK25110035 (NDC 51991-817-01, 100-count bottles, expiry May 2029). The affected lot shared intermediate material with a separate lot that was never released to market but in which metal contamination had already been identified. Breckenridge states no adverse events assessed as related to this recall have been reported to date.

The risk profile is clinically specific: ingestion of metallic particulates carries potential for lacerations of soft tissue in the oral cavity, esophagus, stomach, or intestine. Distribution of the recalled lot ran nationwide to wholesalers and pharmacies between October 26 and November 4, 2026, establishing a defined but broad supply-chain footprint that downstream dispensers must now map against their own inventory records.

For QA and supply-chain teams, the operational mechanics here are instructive. The contamination was not detected in the released lot directly, it was inferred from a shared intermediate, meaning the control failure preceded final dosage form manufacturing. That sequence points to gaps in intermediate material traceability and batch genealogy documentation under 21 CFR Part 211 rather than finished-product testing alone. Wholesalers, pharmacies, and retail entities are directed to quarantine affected stock immediately and notify sub-accounts to the retail level; recall coordination is routed through Qualanex, Breckenridge's designated recall service provider, reachable at 1-855-736-0807 or [email protected].

The recall is being conducted with FDA knowledge, and adverse events or quality complaints may be submitted through the MedWatch program at fda.gov/medwatch/report.htm.

The extent to which Breckenridge's CAPA documentation addresses intermediate material segregation at the contract site will likely determine the scope of any subsequent FDA inspection activity tied to this event.

Source: FDA MedWatch Safety Alerts RSS Feed via fda.gov, November 20, 2026.

Read the original release ↗
TopicsNews
Vaibhavi M.
Written by
Vaibhavi M.
Subject Matter Expert · Pharma Now

Reporting on the science, business and regulation shaping the pharmaceutical industry.

Discussion

Loading discussion…

More from Pharma News

All stories →